Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Danaher Corporation — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $25.54 (market cap $142.30B), while Danaher Corporation trades at $197.72 (market cap $140.88B). The key difference: Banco Bilbao Vizcaya Argentaria SA and Danaher Corporation are close in size by market cap, and Banco Bilbao Vizcaya Argentaria SA pays the higher dividend (4.2%). Which is the better fit depends on your goals.
| BBVA | DHR | |
|---|---|---|
Market Cap | $142.30B | $140.88B |
Sector | Financials | Health |
52-Week High | $26.14 | $242.05 |
52-Week Low | $14.73 | $161.91 |
Dividend Yield | 4.2% | 0.8% |
Enterprise Value | — | $153.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $25.39, down 1.17% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 26.51% net income margin and 18.67% ROE. Recent earnings beat expectations in Q1 2026, and revenue has grown steadily from $28.2B in 2022 to $39.4B in 2025. Positive analyst sentiment is reflected in a 53.85% buy rating, though legal and regulatory risks from ongoing probes in Spain present headwinds.
The outlook for BBVA remains positive given robust profitability and analyst support, but investors should weigh the stock's attractive valuation against litigation risks and sector volatility. Upside potential exists if earnings continue to exceed forecasts, but legal developments could pressure the share price near-term.
Danaher (DHR) trades at $199.05, showing minimal daily change, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 58.94% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights the acquisition of Masimo and new product launches in its SCIEX division, indicating growth initiatives. Cash flow improved in 2025 to a net inflow of $2.54 billion, though revenue growth remains modest.
The outlook is positive with a consensus price target of $211.33, representing a 6% upside, and 69% of analysts rate it a buy. Risks include slowing revenue growth, high valuation multiples, and integration challenges from acquisitions. The stock offers a dividend yield supported by stable cash flows, but investors should monitor competitive pressures in the life sciences sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
